Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Shafia Rahman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4751-0852; OpenAlex author ID A5075537143. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 5 papers, 1 trial

Papers 9

  1. Dual targeting of DHODH and SLC29A1 overcomes metabolic resistance and enhances antitumor immune responses in PDAC. Co-author DOI 10.1158/1535-7163.mct-26-0461↗
  2. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  3. Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review. Last author DOI 10.3389/fonc.2026.1901721↗
  4. Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review. Last author DOI 10.3389/fonc.2026.1955091↗
  5. Advances in KRAS-Targeted Therapies for Pancreatic Cancer. Last author DOI 10.3390/cancers18182961↗
  6. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  7. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  8. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  9. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results. Co-author DOI 10.3390/cancers15153967↗

Trials 1

  1. DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Principal investigator NCT07705919↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 5 shared papers, 2023–2026 · strength 1.05
  2. Supriya Peshin · 3 shared papers, 2026 · strength 1.02
  3. Ehab Takrori · 3 shared papers, 2026 · strength 1.02
  4. Ashish Manne · 4 shared papers, 2024–2026 · strength 0.79
  5. Mary E. Dillhoff · 4 shared papers, 2024–2026 · strength 0.79
  6. Anne M. Noonan · 4 shared papers, 2024–2026 · strength 0.79
  7. Harrison Kim · 2 shared papers, 2026 · strength 0.63
  8. Mark P. Rubinstein · 2 shared papers, 2026 · strength 0.63
  9. Aslam M. Ejaz · 3 shared papers, 2024–2026 · strength 0.57
  10. Timothy Michael Pawlik · 2 shared papers, 2025–2026 · strength 0.48
  11. Eric David Miller · 2 shared papers, 2024–2025 · strength 0.37
  12. Kenneth L Pitter · 2 shared papers, 2024–2025 · strength 0.37
  13. Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
  14. Upender Manne · 2 shared papers, 2024 · strength 0.31
  15. Kannan Thanikachalam · 2 shared papers, 2024 · strength 0.31
  16. Ashwini Kumar Esnakula · 2 shared papers, 2024 · strength 0.31
  17. Wancai Yang · 2 shared papers, 2024 · strength 0.31
  18. Lianbo Yu · 2 shared papers, 2024 · strength 0.31
  19. Ankur Sheel · 2 shared papers, 2024 · strength 0.31
  20. Anup Kasi · 2 shared papers, 2024 · strength 0.31
  21. Ravi Kumar Paluri · 2 shared papers, 2024 · strength 0.31
  22. Robert Connor Chick · 1 shared paper, 2023 · strength 0.26
  23. Andrew J. Gunderson · 1 shared paper, 2023 · strength 0.26
  24. Mitch A. Phelps · 1 shared paper, 2026 · strength 0.26
  25. Fredrik I. Thege · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.